DDR1 and neoplasm: Although compounds like imatinib (38), nilotinib (39), and dasatinib (39) have been identified as DDR1 inhibitors, their lack of specificity—stemming from their original design to target ABL kinases—limits their effectiveness, particularly within the complex tumor microenvironment.